The study team implemented sentinel-site surveillance in northern Kenya, focusing on every malaria case among children eligible for SMC who presented at selected health facilities. They investigated each case to map gaps in delivery, uptake, and chemoprevention effectiveness. The investigators designed this approach to work in a setting with high population mobility, long distances between settlements, and dispersed communities—conditions that complicate routine SMC campaigns. The surveillance model captured real-time operational failures as well as biological signals of emerging drug resistance.
Household travel emerged as the most frequent explanation for missed SMC cycles, the cohort showed. Caregiver refusal was reported less often. This pattern suggests access and mobility issues rather than broad community opposition to SMC. Investigators noted that these logistic obstacles align with the pastoralist context of northern Kenya—frequent movement, widely scattered households, and long travel times to fixed distribution points. The source did not provide detailed quantitative breakdowns of all individual reasons beyond the comparative prominence of travel over refusal.
Data indicated that more than one-third of children presenting with malaria had missed their most recent SMC cycle. The study team also observed that roughly 15% of presenting children were within a few days of receiving their next scheduled SMC cycle. Those two observations together point to timing and coverage gaps: missed doses are common, and a subset of cases occur in the interval before the next prophylactic round. The authors used these findings to flag windows of vulnerability that program managers could address through targeted distribution or timing adjustments.
Molecular surveillance assessed parasite alleles linked to resistance to sulfadoxine-pyrimethamine and to amodiaquine. The prevalence of the SP-associated quintuple mutant haplotype IRNI/GEAA (PfDHFR 51I, 59R, 108N; PfDHPS 437G, 540E)—a haplotype associated in other reports with high-level SP resistance—was observed in 13.4% of infections. The authors emphasized that this prevalence was considerably lower than levels reported elsewhere in East Africa. The allele associated with reduced susceptibility to amodiaquine was not detected in the sampled infections. The study team also reported that resistance-associated mutations were more common among children who had recently received SPAQ, consistent with intrahost selection following chemoprevention. The source did not report additional genotyping frequencies or p-values in the abstract.
Field teams relayed sentinel findings to program managers, enabling targeted redistribution of SMC commodities and focused community sensitization in identified geographic gaps. The surveillance system functioned both as an operational quality-control tool and as a molecular early-warning system. Investigators reported that this dual function—documenting delivery failures while tracking resistance markers—allowed near real-time prioritization of interventions in hard-to-reach, mobile populations.
The authors confirmed institutional ethics approval from the Moi Teaching and Referral Hospital/Moi University Institutional Scientific and Ethics Review Committee (Approval number FAN:005076). They reported that data are being uploaded to the NCBI Sequence Read Archive (SRA) for public access. The investigators concluded that, although current prevalence of SP- and AQ-associated resistance markers that could threaten SPAQ effectiveness is low in their sample, the observed enrichment of resistance mutations among recently treated children indicates selection pressure. The authors therefore recommended continued molecular surveillance as SMC is scaled up in northern Kenya.
Limitations and documented unanswered questions remain specific. The source did not provide detailed breakdowns of all reasons for missed cycles beyond the prominence of household travel, nor did it report comprehensive allele frequency tables or trial-level statistics in the abstract. The study did not report operational metrics such as coverage denominators for the entire target population in the provided text. Investigators noted that ongoing monitoring is required to determine whether the current low prevalence of the SP quintuple mutant will remain stable as SMC coverage expands, and whether intrahost selection will translate into clinically meaningful loss of SPAQ efficacy over time.